165 related articles for article (PubMed ID: 24634384)
1. Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response.
Gao Q; Patani N; Dunbier AK; Ghazoui Z; Zvelebil M; Martin LA; Dowsett M
Clin Cancer Res; 2014 May; 20(9):2485-94. PubMed ID: 24634384
[TBL] [Abstract][Full Text] [Related]
2. Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Gao Q; López-Knowles E; Cheang MCU; Morden J; Ribas R; Sidhu K; Evans D; Martins V; Dodson A; Skene A; Holcombe C; Mallon E; Evans A; Bliss JM; Robertson J; Smith I; Martin LA; Dowsett M;
Breast Cancer Res; 2019 Dec; 22(1):2. PubMed ID: 31892336
[TBL] [Abstract][Full Text] [Related]
3. Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
Ghazoui Z; Buffa FM; Dunbier AK; Anderson H; Dexter T; Detre S; Salter J; Smith IE; Harris AL; Dowsett M
Clin Cancer Res; 2011 May; 17(9):3005-12. PubMed ID: 21325071
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Dunbier AK; Ghazoui Z; Anderson H; Salter J; Nerurkar A; Osin P; A'hern R; Miller WR; Smith IE; Dowsett M
Clin Cancer Res; 2013 May; 19(10):2775-86. PubMed ID: 23493347
[TBL] [Abstract][Full Text] [Related]
5. Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
López-Knowles E; Wilkerson PM; Ribas R; Anderson H; Mackay A; Ghazoui Z; Rani A; Osin P; Nerurkar A; Renshaw L; Larionov A; Miller WR; Dixon JM; Reis-Filho JS; Dunbier AK; Martin LA; Dowsett M
Breast Cancer Res; 2015 Mar; 17(1):35. PubMed ID: 25888249
[TBL] [Abstract][Full Text] [Related]
6. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
[TBL] [Abstract][Full Text] [Related]
7. Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.
Leal MF; Haynes BP; Schuster E; Yeo B; Afentakis M; Zabaglo L; Martins V; Buus R; Dodson A; Cheang MCU; Smith IE; Martin LA; Dowsett M
Clin Cancer Res; 2019 Dec; 25(24):7485-7496. PubMed ID: 31548345
[TBL] [Abstract][Full Text] [Related]
8. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
9. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
Anderson H; Hills M; Zabaglo L; A'hern R; Leary AF; Haynes BP; Smith IE; Dowsett M
Ann Oncol; 2011 Aug; 22(8):1770-6. PubMed ID: 21285137
[TBL] [Abstract][Full Text] [Related]
10. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
[TBL] [Abstract][Full Text] [Related]
11. Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.
Turnbull AK; Arthur LM; Renshaw L; Larionov AA; Kay C; Dunbier AK; Thomas JS; Dowsett M; Sims AH; Dixon JM
J Clin Oncol; 2015 Jul; 33(20):2270-8. PubMed ID: 26033813
[TBL] [Abstract][Full Text] [Related]
12. HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
Bergamino MA; López-Knowles E; Morani G; Tovey H; Kilburn L; Schuster EF; Alataki A; Hills M; Xiao H; Holcombe C; Skene A; Robertson JF; Smith IE; Bliss JM; Dowsett M; Cheang MCU;
EBioMedicine; 2022 Sep; 83():104205. PubMed ID: 35985932
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers.
Schuster EF; Lopez-Knowles E; Alataki A; Zabaglo L; Folkerd E; Evans D; Sidhu K; Cheang MCU; Tovey H; Salto-Tellez M; Maxwell P; Robertson J; Smith I; Bliss JM; Dowsett M
Nat Commun; 2023 Jul; 14(1):4017. PubMed ID: 37419892
[TBL] [Abstract][Full Text] [Related]
14. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
15. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
16. Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.
Lu Y; You M; Ghazoui Z; Liu P; Vedell PT; Wen W; Bode AM; Grubbs CJ; Lubet RA
Cancer Prev Res (Phila); 2013 Nov; 6(11):1151-61. PubMed ID: 24067424
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
18. Molecular response to aromatase inhibitor treatment in primary breast cancer.
Mackay A; Urruticoechea A; Dixon JM; Dexter T; Fenwick K; Ashworth A; Drury S; Larionov A; Young O; White S; Miller WR; Evans DB; Dowsett M
Breast Cancer Res; 2007; 9(3):R37. PubMed ID: 17555561
[TBL] [Abstract][Full Text] [Related]
19. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
20. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.
Ribas R; Ghazoui Z; Gao Q; Pancholi S; Rani A; Dunbier A; Dowsett M; Martin LA
Breast Cancer Res; 2014 Oct; 16(5):447. PubMed ID: 25358600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
